{"id":"hla-a","name":"HLA-A","symbol":"HLA-A","route":"/targets/hla-a/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4931","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000206503","uniprot":"https://www.uniprot.org/uniprotkb/P04439/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P04439","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2632","open-targets":"https://platform.opentargets.org/target/ENSG00000206503","civic":"https://civicdb.org/genes/3105/summary","oncokb":"https://www.oncokb.org/gene/HLA-A","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HLA-A","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=HLA-A","depmap":"https://depmap.org/portal/gene/HLA-A?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000206503-HLA-A","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3105","omim":"https://www.omim.org/entry/142800"}],"products":[{"id":"afamitresgene-autoleucel","name":"Afamitresgene autoleucel","status":"approved","modality":"TCR-T (MAGE-A4)","route":"/drugs/afamitresgene-autoleucel/"},{"id":"brenetafusp","name":"Brenetafusp","status":"phase-3","modality":"ImmTAC (PRAME TCR × CD3 bispecific)","route":"/drugs/brenetafusp/"},{"id":"letetresgene-autoleucel","name":"Letetresgene autoleucel","status":"phase-2","modality":"TCR-T (NY-ESO-1)","route":"/drugs/letetresgene-autoleucel/"},{"id":"tebentafusp","name":"Tebentafusp","status":"approved","modality":"ImmTAC (TCR×CD3 bispecific)","route":"/drugs/tebentafusp/"}],"trials":[{"id":"prism-mel-301","name":"PRISM-MEL-301","nct":"NCT06112314","phase":"3","status":"recruiting"},{"id":"nct05549297","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","nct":"NCT05549297","phase":"3","status":"recruiting"},{"id":"nct04044768","name":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","nct":"NCT04044768","phase":"2","status":"active"},{"id":"ignyte-eso","name":"IGNYTE-ESO","nct":"NCT03967223","phase":"2","status":"positive"},{"id":"imcgp100-202","name":"IMCgp100-202","nct":"NCT03070392","phase":"2","status":"positive"},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","nct":"NCT04262466","phase":"1/2","status":"active"},{"id":"nct05642455","name":"SPEARHEAD-3 Pediatric Study","nct":"NCT05642455","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["adaptimmune","immunocore","us-worldmeds"],"keyPapers":["paper-tcga-lung-squamous-nature-2012"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}